Universidad de Granada Digibug
 

Repositorio Institucional de la Universidad de Granada >
1.-Investigación >
Departamentos, Grupos de Investigación e Institutos >
Departamento de Fisiología >
DFisiología - Artículos >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10481/49085

Title: Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Authors: Reiter, Russel J.
Rosales-Corral, Sergio A.
Tan, Dun-Xian
Acuña Castroviejo, Darío
Qin, Lilan
Yang, Shun-Fa
Xu, Kexin
Issue Date: 17-Apr-2017
Abstract: There is highly credible evidence that melatonin mitigates cancer at the initiation, progression and metastasis phases. In many cases, the molecular mechanisms underpinning these inhibitory actions have been proposed. What is rather perplexing, however, is the large number of processes by which melatonin reportedly restrains cancer development and growth. These diverse actions suggest that what is being observed are merely epiphenomena of an underlying more fundamental action of melatonin that remains to be disclosed. Some of the arresting actions of melatonin on cancer are clearly membrane receptor-mediated while others are membrane receptor-independent and involve direct intracellular actions of this ubiquitously-distributed molecule. While the emphasis of melatonin/cancer research has been on the role of the indoleamine in restraining breast cancer, this is changing quickly with many cancer types having been shown to be susceptible to inhibition by melatonin. There are several facets of this research which could have immediate applications at the clinical level. Many studies have shown that melatonin’s co-administration improves the sensitivity of cancers to inhibition by conventional drugs. Even more important are the findings that melatonin renders cancers previously totally resistant to treatment sensitive to these same therapies. Melatonin also inhibits molecular processes associated with metastasis by limiting the entrance of cancer cells into the vascular system and preventing them from establishing secondary growths at distant sites. This is of particular importance since cancer metastasis often significantly contributes to death of the patient. Another area that deserves additional consideration is related to the capacity of melatonin in reducing the toxic consequences of anti-cancer drugs while increasing their efficacy. Although this information has been available for more than a decade, it has not been adequately exploited at the clinical level. Even if the only beneficial actions of melatonin in cancer patients are its ability to attenuate acute and long-term drug toxicity, melatonin should be used to improve the physical wellbeing of the patients. The experimental findings, however, suggest that the advantages of using melatonin as a co-treatment with conventional cancer therapies would far exceed improvements in the wellbeing of the patients.
Sponsorship: Shun-Fa Yang, Grant #CHS-2016-E-002-Y2.
Publisher: MDPI
Keywords: Ionizing radiation
Antioxidant
Free radicals
Apoptosis
Angiogenesis
Molecular mechanisms
Invasion
Breast
Prostate
Melatonin receptors
Chemotherapy
URI: http://hdl.handle.net/10481/49085
ISSN: 1422-0067
Rights : Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License
Citation: Reiter, R.J.; et al. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. International Journal of Molecular Sciences, 18(4): 843 (2017). [http://hdl.handle.net/10481/49085]
Appears in Collections:DFisiología - Artículos

Files in This Item:

File Description SizeFormat
Reiter_MelatoninAntiCancer.pdf5.87 MBAdobe PDFView/Open
Recommend this item

This item is licensed under a Creative Commons License
Creative Commons

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! OpenAire compliant DSpace Software Copyright © 2002-2007 MIT and Hewlett-Packard - Feedback

© Universidad de Granada